Drug intelligence / Profile preview

JT821

Development stage: Unknown
Lead developer: Jiate (Beijing) Medical Technology
Administration: Oral

Overview

JT821 is a specialized ketogenic diet formulation developed by Jiate (Beijing) Medical Technology for the treatment of neurodegenerative diseases, including Alzheimer's disease and behavioral variant frontotemporal dementia (bvFTD). As a medical food or nutritional intervention, it is designed to induce therapeutic ketosis, a metabolic state where the body utilizes ketone bodies (such as beta-hydroxybutyrate) instead of glucose as the primary energy source for the brain. This approach aims to bypass the impaired glucose metabolism frequently observed in dementia patients, potentially providing neuroprotective benefits, reducing neuroinflammation, and improving cognitive function. JT821 is currently being evaluated in multi-center, randomized clinical trials in China.

Other names: ketogenic diet formulation JT821

Beyond the preview

Go deeper on JT821.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JT821.

Explore the full profile